Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Hematide clinical results demonstrate potent effect on red blood cell production
July 6th, 2005
Affymax, Inc., announced the presentation of two posters detailing preclinical data and phase I study results for its lead product candidate, Hematide, a peptide-based erythropoiesis stimulating agent (ESA). Hematide is being developed for the treatment of anemia in patients with chronic kidney disease and cancer. Hematide is currently being evaluated in a phase II clinical trial investigating its safety, pharmacodynamics and pharmacokinetics in patients with chronic kidney disease who are not on dialysis. The presentations were made on June 4, at the European Hematology Association meeting in Stockholm. "The preclinical and phase I clinical results...
Source: Biotech Week (2005-07-06)
|
